KRAS and colorectal carcinoma: Palbociclib is also involved in a phase II clinical trial (ClinicalTrials.gov Identifier: NCT03981614), where it is used in combination with chemotherapeutic drug TAS-102 for KRAS/NRAS metastatic or unresectable CRC.